New drug patents applied by Howson pharmaceutical in recent years

Wo2005105151; cn102233130 thymosin derivative, suspected to be PEGylated thymosin α 1 in the treatment of hepatitis B Cn1690073 estrogen receptor modulator, fulvestrant analogue, for the treatment of breast cancer Cn101190890 adrenal α 1-receptor antagonist for dysuria Cn102796079; cn102816146; cn102816147 BCR ABL inhibitor, in the treatment of chronic myeloid leukemia, i.e flumatinib Wo2008138184 (jointly owned by Hengrui and hausen) VEGFR / PDGFR inhibitor, sunitinib analogue, for tumor treatment Wo2009079910; wo2009079911, pegylated erythropoietin, is suspected to be used to treat anemia Wo2008089636; wo2009094866 (shared by Hengrui and hausen) DPP-4 inhibitor, wiggliptin analogue, for the treatment of type II diabetes mellitus, it is suspected to be berggliptin Wo2011012080 GLP-1 analogue, for the treatment of type II diabetes mellitus, suspected to be losenapeptide or nori glycopeptide Wo2012155780; cn102241775 PEGylated GLP-1 analog for the treatment of type II diabetes mellitus, suspected to be pegylated losenapeptide Cn102030709 vasopressin receptor antagonist for the treatment of hypertension Wo2012019427 PARP inhibitor, olaparib analogue, for the treatment of breast cancer and ovarian cancer Wo2012097697 Ang II receptor antagonist, for the treatment of hypertension, i.e azilsartan Ep2678021 (wo2012116050) ALK inhibitor, clozatinib analogue, was used to treat ALK positive non-small cell lung cancer.